REFERENCES
- Rosenberg M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82
- Woods E R, Grace E, Havens K K, et al. Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. Am J Obstet Gynecol 1992; 166: 901–7
- Muhn P, Ksrattenmacher R, Beier S, et al. Drospirenone, a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995; 51: 99–110
- Fuhrmann U, Krattenmacher R, Slater E P, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–51
- Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–42
- Oelkers W, Foidart J M, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin— aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21
- Rosenbaum P, Schmidt W, Helmerhorst F M, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000; 5: 16–24
- Burke B M, Cunliffe W J. The assessment of acne vulgaris -the Leeds technique. Br J Dermatol 1984; 111: 83–92
- Oddens B J. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning and sterilization among 1466 women. Contraception 1999; 59: 277–86